According to filings with the U.S. Securities and Exchange Commission, Stingray Therapeutics is raising $5,230,297.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jonathan Northrup played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Stingray Therapeutics
Stingray Therapeutics is working on an exciting new effort to fight cancer with 2nd generation immune-oncology agents. Current efforts in this field are the equivalent of trying to do it with one hand of the immune system tied behind its back. At Stingray, we are unleashing the full immune system to take this fight to an entirely new level. The first generation of immune-oncology therapies, checkpoint inhibitors, leverage adaptive immunity to counter cancer’s immunosuppressive “checkpoints.” However, many patients develop resistance or are non- responsive to treatment given tumors are “cold” (cancer unrecognized by adaptive immune system). These tumors are cold because the cancer has turned off innate immunity. Innate immunity is your other major arm of the immune system. Innate immunity is your first immune response to a threat and also a “beacon” to adaptive immunity to reveal the threat and tell adaptive immunity where to go to fight. Immunotherapy drugs like Stingray’s open up innate immunity to reveal the cancer cells previously hidden from adaptive immunity. This allows the immune system to attack and kill the cancer.

To learn more about Stingray Therapeutics, visit http://stingraytx.com/

Contact:
Jonathan Northrup, Chief Executive Officer
713-503-7707

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.